Corcept Therapeutics Incorporated (CORT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Corcept Therapeutics Incorporated (CORT) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How CORT Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $761.4M | 98.3% | 5.9% | $99.7M | $141.8M | 5.8% |
| FY 2024 | $675.0M | 98.4% | 20.3% | $141.2M | $196.1M | 17.3% |
| FY 2023 | $482.4M | 44% | 22.2% | $106.1M | $105.0M | 2.7% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CORT)
- ✓Live walkthrough of CORT's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CORT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +12.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CORT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CORT. Explore sector supply chains on /butterfly.
CORT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Corcept Therapeutics Incorporated (CORT)?
In FY 2025 (10-K), CORT converted $761.4M of revenue into a 98.3% gross margin, 5.9% operating margin, and $141.8M in free cash flow (18.6% FCF margin).